{"id":8613,"date":"2021-04-02T09:50:51","date_gmt":"2021-04-02T16:50:51","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8613"},"modified":"2021-04-06T09:51:38","modified_gmt":"2021-04-06T16:51:38","slug":"interim-report-safety-and-immunogenicity-of-an-inactivated-vaccine-against-sars-cov-2-in-healthy-chilean-adults-in-a-phase-3-clinical-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/02\/interim-report-safety-and-immunogenicity-of-an-inactivated-vaccine-against-sars-cov-2-in-healthy-chilean-adults-in-a-phase-3-clinical-trial\/","title":{"rendered":"Interim Report Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Interim results for the phase 3 clinical trial (n=397) of the SARS-CoV-2 inactivated-virus vaccine CoronaVac (SinoVac BioTech) conducted in Chile indicate the vaccine is safe to use and induces neutralizing antibody production against the SARS-CoV-2 spike protein. Among participants receiving two doses of the vaccine (n=239) or placebo (n=80) 2 weeks apart, no serious adverse events were reported up to 28 days after the second dose, and symptoms resolved within two days. Seroconversion for anti-spike IgG among vaccinated individuals aged 18-59 years was 48% at day 14 and 95% at day 42. Among individuals aged \u226560 years old, seroconversion was 18% at day 14 and 88% at day 42. Neutralizing antibodies were not detected among vaccinated individuals at day 14, but were detected at day 42 in 97% individuals aged 18-59 years and 100% of those age \u226560 years. No significant differences in cell-mediated immunity were observed between the two age groups.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Bueno et al.\u00a0(Apr 1, 2021). Interim Report Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial. Pre-print downloaded Apr 2 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.03.31.21254494\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.03.31.21254494<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Interim results for the phase 3 clinical trial (n=397) of the SARS-CoV-2 inactivated-virus vaccine CoronaVac (SinoVac BioTech) conducted in Chile indicate the vaccine is safe to use and induces neutralizing antibody production against the SARS-CoV-2 spike protein. Among participants receiving two doses of the vaccine (n=239) or placebo (n=80) 2 weeks apart,&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/02\/interim-report-safety-and-immunogenicity-of-an-inactivated-vaccine-against-sars-cov-2-in-healthy-chilean-adults-in-a-phase-3-clinical-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-8613","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8613"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8613\/revisions"}],"predecessor-version":[{"id":8614,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8613\/revisions\/8614"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8613"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}